Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.

MLA

Lange, Christoph, et al. “Availability of Drugs and Resistance Testing for Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaL(M)) Regimen for Rifampicin-Resistant Tuberculosis in Europe: Author’s Response.” Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 30, no. 9, Sept. 2024, pp. 1207–08. EBSCOhost, https://doi.org/10.1016/j.cmi.2024.06.009.

APA

Lange, C., Kherabi, Y., Guglielmetti, L., Duarte, R., & Günther, G. (2024). Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author’s response. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 30(9), 1207–1208. https://doi.org/10.1016/j.cmi.2024.06.009

Chicago

Lange, Christoph, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, and Gunar Günther. 2024. “Availability of Drugs and Resistance Testing for Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaL(M)) Regimen for Rifampicin-Resistant Tuberculosis in Europe: Author’s Response.” Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 30 (9): 1207–8. doi:10.1016/j.cmi.2024.06.009.